---
title: "Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits"
ocid: "ocds-h6vhtk-02bcb3"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02bcb3"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02bcb3.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02bcb3.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST)"
published: "2021-06-16"
---

# Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits

Buyer: NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST)  
Current stage: Award  
OCID: ocds-h6vhtk-02bcb3

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02bcb3)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02bcb3.json)

## Summary

The NHS Wales Shared Services Partnership-Procurement Services, hosted by Velindre University NHS Trust, is conducting a procurement process for the purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits. This contract falls within the health industry and is located in Cardiff, UK. The procurement is at the award stage, having a value of £232,200, with the contract estimated to commence in July 2021. This contract is categorized under laboratory reagents and is being awarded through a limited procurement method without prior publication of a call for competition, meaning it was directed specifically to a capable supplier.

This tender presents a significant opportunity for companies specialized in laboratory reagents, particularly those supplying diagnostic testing kits for genetic testing related to cancer treatment. Businesses that can demonstrate capability in providing validated IVD-marked technologies and have the ability to meet stringent quality and cost assessments will be well-positioned to compete. The contract will also allow for potential growth in product offerings and services associated with genomics and healthcare testing, making it highly relevant for suppliers in the biotech and medical device sectors.

## Notice

All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.

### Lot Information

Lot 1

All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. The test has continued to grow in demand across Wales for an established DPYD service and as a consequence AWMGL is now required to advertise their intention award a contract to Yourgene Health UK without prior advertisement. The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons; The test has already been validated by the laboratory as it has been used for a number of years, therefore meets the standards required to deliver the service. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the laboratory and would be extremely detrimental to patient care. The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing. The equipment needed for the test is already in place. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment. Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test. Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above) NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGL, for the supply of a The Elucigene DPYD assay provided by Yourgene Health UK Limited, for the unique reasons outlined above. The contract is estimated to commence in July 2021, for a period of two years (to be awarded for 12 months with the option to extend for a further 12 months) for estimated quantity of 144 kits (3600 samples) per annum. The contract will include all associated services.

### Procurement Information

All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient. The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons; The test has already been validated in the lab and is confirmed as being suitable for use. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the lab and be extremely detrimental to patient care. The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing. The equipment needed for the test is already in place and maintained. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment. Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test. Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above)

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/013632-2021 |
| Notice type | Award Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Limited |
| Procurement method details | Award procedure without prior publication of a call for competition |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 16 Jun 2021 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 31 May 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £232,200 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Not specified |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS WALES SHARED SERVICES PARTNERSHIP-PROCUREMENT SERVICES (HOSTED BY VELINDRE UNIVERSITY NHS TRUST) |
| Locality | CARDIFF |
| Post town | Cardiff |
| Postcode | CF14 4TT |
| Country | Wales |
| ITL 1 | TLL Wales |
| ITL 2 | TLL5 South East Wales |
| ITL 3 | TLL52 Cardiff and Vale of Glamorgan |
| Local authority | Cardiff |
| Electoral ward | Heath |
| Westminster constituency | Cardiff North |
| Delivery location | TLL22 Cardiff and Vale of Glamorgan |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | YOURGENE HEALTH |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33696500 - Laboratory reagents

## Release History

- 16 Jun 2021 at 13:54 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/013632-2021

## Notice URLs

- http://nwssp.nhs.wales/ourservices/procurement-services/
- https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111498
- https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02bcb3. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02bcb3.json.